Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-010-0927-9PMID 20976449PMCID PMC3202216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars Article: Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science 2003. 299: 1057-1061.

  2017cited by this paper
• From the Editors

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• CD8+CD28− cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients

  2010cited by this paper
• Increased circulating regulatory T cells (CD4+CD25+CD127−) contribute to lymphocyte anergy in septic shock patients

  2009cited by this paper
• CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.

  2009cited by this paper
• Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

  2009cited by this paper
• Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas

  2009cited by this paper
• Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

  2009cited by this paper
• Promising novel immunotherapies and combinations for prostate cancer.

  2009cited by this paper
• Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?

  2009cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

  2008cited by this paper
• Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

  2008cited by this paper
• Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

  2008cited by this paper
• Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

  2008cited by this paper
• CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

  2008cited by this paper
• Role of forkhead box protein 3 expression in invasive breast cancer.

  2007cited by this paper
• FOXP3[+] regulatory T cells affect the development and progression of hepatocarcinogenesis

  2007cited by this paper
• FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis

  2007cited by this paper
• Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

  2007cited by this paper
• Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.

  2007cited by this paper
• Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells

  2007cited by this paper
• Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells

  2006cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1

  2006cited by this paper
• CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells

  2006cited by this paper
• Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.

  2005cited by this paper
• Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

  2005cited by this paper
• Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer

  2005cited by this paper
• Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma

  2005cited by this paper
• Natural versus adaptive regulatory T cells.

  2005cited by this paper
• Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

  2005cited by this paper
• Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia

  2005cited by this paper
• Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

  2005cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA‐4 expression

  2004cited by this paper
• Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

  2004cited by this paper
• CD4+CD25+ Suppressor Lymphocytes in the Circulation of Patients Immunized Against Melanoma Antigens

  2003cited by this paper
• CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies

  2003cited by this paper
• Supporting Online Material

  2003cited by this paper
• Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

  2003cited by this paper
• Tolerance, DCs and tryptophan: much ado about IDO.

  2003cited by this paper
• Modulation of tryptophan catabolism by regulatory T cells

  2003cited by this paper
• Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells

  2003cited by this paper
• Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?

  2002cited by this paper
• Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1

  2002cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002cited by this paper
• A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood.

  2001cited by this paper
• A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood1

  2001cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

  2000cited by this paper
• Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

  2000cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma

  1989cited by this paper

• Combined immunotherapy employing Wilms' tumor 1 peptide‐pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer

  2025cites this paper
• New approaches and prospects of immunotherapy and gene therapy for prostate cancer

  2024cites this paper
• mRNA cancer vaccines: Advances, trends and challenges

  2022cites this paper
• The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.

  2021cites this paper
• Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies

  2021cites this paper
• Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients

  2021cites this paper
• Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

  2020cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review).

  2018cites this paper
• The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.

  2017cites this paper
• Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

  2017cites this paper
• The immune system in cancer metastasis: friend or foe?

  2017cites this paper
• Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer.

  2017cites this paper
• The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy

  2016cites this paper
• The evolving role of immunotherapy in prostate cancer

  2016cites this paper
• Immune Therapy for Prostate Cancer

  2016cites this paper
• Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation.

  2016cites this paper
• Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

  2015cites this paper
• Integrating Immunotherapies in Prostate Cancer

  2015cites this paper
• Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells

  2015cites this paper
• Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV

  2015cites this paper
• Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.

  2015cites this paper
• Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges

  2015cites this paper
• Fundamental Principles of Raising an Antitumour Immune Response in Vivo: A Complex Model, a Case Report, and a Perspective

  2014cites this paper
• p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

  2014influential citation
• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

  2014cites this paper
• Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches

  2014cites this paper
• A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

  2014cites this paper
• Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

  2014cites this paper
• New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials.

  2014cites this paper
• The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors

  2014cites this paper
• Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).

  2013cites this paper
• Immunotherapy and Immune Evasion in Prostate Cancer

  2013cites this paper
• Tick-Borne Encephalitis (TBE) and Hepatitis B Nonresponders Feature Different Immunologic Mechanisms in Response to TBE and Influenza Vaccination with Involvement of Regulatory T and B Cells and IL-10

  2013cites this paper
• Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials

  2013influential citation
• Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer

  2013cites this paper
• Demystifying Immunotherapy in Prostate Cancer: Understanding Current and Future Treatment Strategies

  2013cites this paper
• Effects of conventional therapeutic interventions on the number and function of regulatory T cells

  2013influential citation
• Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

  2013cites this paper
• A flow cytometry based assay for the enumeration of regulatory T cells in whole blood.

  2013cites this paper
• Therapeutic cancer vaccines: past, present, and future.

  2013cites this paper
• Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

  2013cites this paper
• Approaches to Immunologic Monitoring of Clinical Trials

  2013cites this paper
• Q 1 2 Immune Q 2 Impact Induced by PROSTVAC ( PSA-TRICOM ) , Q 3 3 a Therapeutic Vaccine for Prostate Cancer 4 5

  2013cites this paper
• T and B Cells and IL-10 Vaccination with Involvement of Regulatory Tick-Borne Encephalitis and Influenza Immunologic Mechanisms in Response to Nonresponders Feature Different Tick-Borne Encephalitis and Hepatitis B

  2013cites this paper
• Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response

  2012cites this paper
• Regulatory T cells: a review.

  2012cites this paper
• Current world literature.

  2012cites this paper
• Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer

  2012cites this paper
• Therapeutic cancer vaccines: current status and moving forward.

  2012cites this paper
• Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer.

  2012cites this paper
• Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy

  2011cites this paper
• Immunotherapy for prostate cancer: biology and therapeutic approaches.

  2011cites this paper
• Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3

  2011cites this paper
• From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

  2011cites this paper
• Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.

  2011cites this paper
• Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

  2011cites this paper